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Abstract: Epidemiologic studies indicate that
most risk factors for breast cancer are related
to reproductive and hormonal factors. The
evaluation of associations between breast
cancer risk and genetic polymorphisms in
enzymes involved in hormone metabolism
may be a cost effective manner in which to
determine
individual
breast
cancer
susceptibility. A number of molecular
epidemiologic studies have been conducted to
evaluate associations between polymorphic
genes involved in steroid hormone

Breast cancer is the most commonly occurring cancer
among women, and the morbidity rate of this disease
continues to rise, whereas the mortality rate is declining
due to more advanced diagnosis and treatment
techniques (1). Fewer breast cancer cases can be
explained by rare, highly penetrant genes such as BRCA1,
BRCA2 and TP53. In principle, common, low penetrance
genes could explain the majority of breast cancer cases
(2).
Endogenous steroid hormones are important in the
development and progression of breast cancer. Steroid
hormones exert growth-promoting effects and induce
breast cell proliferation by binding to intracellular
receptors and regulating gene transcription (3). Several
breast cancer risk factors are thought to act by
influencing lifetime exposure to steroid hormones. The
rate of increase in breast cancer incidence declines after
menopause, probably due to lower circulating estrogen
and progestrone levels. Age at menarche, age at
menopause,
postmenopausal
obesity,
and
postmenopausal hormone use are well-established breast
cancer risk factors that influence the dose and duration of
estrogen and progestrone exposure (4).
Once formed, estrogens are extensively metabolized
by a number of oxidative and conjugate reactions that can
lead to their deactivation and subsequent elimination (5).

metabolism (i.e., CYP17, CYP19, CYP1A1,
CYP1B1, MnSOD, COMT, and GST) that may
account for a proportion of enzymatic
variability. An evaluation of associations
between breast cancer risk and genetic
polymorphisms in enzymes involved in
hormone metabolism is described in this brief
review.
Key Words: Breast cancer, Genetic
polymorphism, Steroid hormone metabolism

Metabolic activation of 17β-estradiol (E2) has been
postulated to be a factor in mammary carcinogenesis. E2
is metabolized via two major pathways: formation of
catechol estrogens, the 2-OH and 4-OH derivates; and C16α hydroxylation (Figure). The 2-OH and 4-OH catechol
estrogens are oxidized to semiquinones and quinones.
The latter are reactive electrophilic metabolites and are
capable of forming DNA adducts. Further DNA damage
results from quinone-semiquinone redox cycling,
generated by enzymatic reduction of catechol estrogen
quinones to semiquinones and subsequent auto-oxidation
back to quinones. C-16α hydroxylation has also been
suggested to be involved in breast carcinogenesis (6).
Genetic polymorphism has been found to be the basis
of frequently observed individual variation in activities of
drug metabolizing enzymes among human populations.
Striking ethnic dissimilarities, as well as inter-individual
differences, in genes involved in drug metabolism are well
known (7). As observed in drug and chemical metabolism,
there is considerable inter-individual genetic variability in
the metabolic and biosynthetic pathways in
steroidogenesis (5). Many of the enzymes involved in
estrogen metabolism are polymorphically distributed
within the human population (i.e., CYP17, CYP19,
CYP1A1, CYP1B1, MnSOD, COMT, and GST) (5,8).
Inherited alterations in the activity of any of these
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The estradiol synthesis metabolic pathway (8)

enzymes hold the potential to define differences in breast
cancer risk associated with estrogen carcinogenesis.
However, it is evident that no single genotype can be
linked to all breast cancers. Known genetic
polymorphisms in steroid hormone metabolizing enzymes
in human breast cancer are shown in the Table.

Table.

The cytochrome P450 enzyme P45017 has both
17α-hydroxylase and 17,20-lyase activities and catalyzes
two distinct steps in steroid hormone production. In
steroidogenesis, a gene encoding the steroidogenic
enzyme 17α-hydroxylase converts pregnenolone and
progesterone to 17-hydroxypregnenolone and 17-

Known Genetic Polymorphisms in Steroid Hormone Metabolizing Enzymes in Human Breast Cancer (5,8)

Enzyme

Role in Estrogen Metabolism

Allelic variants

CYP17

17-α hydroxylase / C17-20 lyase, catalyzes rate-limiting
step in ovarian and adrenal biosynthesis pathways for
androstenedione

Two variants, enhanced promoter activity

CYP19

Aromatase / estrogen synthetase, converts testosterone and
androstenedione to E2 and E1, respectively

Fourteen variants, may alter splice site
and ability of converting activity

CYP1A1

2-hydroxylase, generates 2-OH CE

Four variants, changed activity

CYP1B1

4-hydroxylase, generates 4-OH CE

Seven variants, changed activity

MnSOD

Manganese superoxide dismutase, converts 2 superoxide
radicals to H2O2 and O2

Two variants, altered protein trafficking

COMT

Methyltransferase, methylates and inactivates CE

Two variants, decreased methylation activity

GST

Glutathione sulfotransferases, decreases oxidative stress
generated during estrogen metabolism

GSTM1, deletion of the entire gene, the null allele
GSTT1, deletion of the entire gene, the null allele
GSTP1, two variants, reduced activity
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hydroxyprogesterone, respectively. In women,
P450c17α is primarily expressed in ovarian theca cells
and adrenal cortex. CYP17 contains a single-base
polymorphism that creates a SP1-type (CCACC box)
promoter and also generates alleles correlating with
different promoter activity (9). Rare mutations in the
coding region of CYP17 have recently been associated
with breast cancer risk. Studies suggest that the A2 allele
of CYP17 elevates endogenous hormone levels, but is not
a strong independent risk factor for breast cancer (10).

acid substitutions. Two of these amino acid substitutions
have been described in exon 3, which encodes the hemebinding domain: codon 432 Val→Leu and codon 453
Asn→Ser; and the other two in codon 48 Arg→Gly and
119 Ala→Ser in exon 2 (15). Polymorphisms are
inherited alterations in the activity of CYP1B1 that hold
the potential to define differences in estrogen metabolism
and, thereby, possibly explain inter-individual differences
in breast cancer risk associated with estrogen-mediated
carcinogenesis (16).

The aromatase enzyme catalyzes the conversion of
androgens to estrogens in the estrogen biosynthesis
pathway. Because increased exposure to estrogen is
considered to be a risk factor for breast cancer,
polymorphic human aromatase gene (CYP19) is a
plausible candidate for low penetrance breast cancer
susceptibility (5). The polymorphic repeat (TTTA) in
intron 5, TCT insertion / deletion in intron 4, and a
substitution in intron 6 of the CYP19 gene create 14
alleles in which to change aromatase activity. Although
there have been numerous reports of different TTTA
repeat alleles being associated with variations in breast
cancer risk, the CYP19 gene has no major role in
common breast cancer incidence (11).

Superoxide dismutase (Mn, Cu, ZnSOD) catalyzes the
dismutation of two superoxide radicals, producing
hydrogen peroxide and oxygen, because ROS, including
those generated by estrogens and their metabolites, may
be involved in breast carcinogenesis and because MnSOD
is a major enzyme involved in the scavenging of free
radicals (5). An amino acid exchange at the 9 position of
MnSOD in the signal peptide sequence apparently alters
the structure of the enzyme, affecting its ability to enter
the mitochondrion. MnSOD alanine allele could be related
to breast cancer risk by having an altered capacity to
reduce oxidative stress (17).

In the breast, CYP1A1 and CYP1B1 are responsible
for the hydroxylation of estrogens to the 2-hydroxy
estrogen (2-OH HE) and 4-OH HEs. In turn, CYP1B1
exceeds CYP1A1 in its catalytic efficiency as E2
hydroxylase and differs from CYP1A1 in its principal site
of catalysis (12). HEs are an important means of
eliminating estrogen. Oxidation occurs via major
pathways, one of which involves C-2 of estradiol,
resulting in the formation of the 2-HE and 4-HE, whereas
the other involves C-16, resulting in the formation of
16α-HE. These products are able to bind to DNA,
creating adducts and subsequently causing gene
mutations. Thus, increased formation of 4-HE and 16αHE has been associated with an elevated risk of breast
cancer (9). To date, at least four polymorphisms have
been described in the human CYP1A1 gene. Two of
these, m1 (a base subsitution in noncoding region) and
m2 (a point mutation in codon 462 of exon 7, leading to
a amino acid subsitution) are associated with increased
breast cancer risk (13,14).
Mutations and polymorphisms have both been
identified in the CYP1B1 gene. Six polymorphisms of the
gene have been described, of which four result in amino

Several Phase II enzymes either inactivate CEs or
protect against estrogen carcinogenesis by detoxifying
products of oxidative damage that may arise on redox
cycling of CEs. Genetic variants of each of these enzymes
involved in CE metabolism have been identified, some
with proven or suspected change in function. Catechol-Omethyltransferase (COMT) is one of several phase II
enzymes responsible for the detoxification of CEs,
including 2-CE and 4-CE by O-methylation and is
polymorphic in the human population with 22% of a
Turkish population being homozygous for a low activity
allele of the enzyme (18,19). The level of COMT activity
is controlled by a DNA exonic polymorphism at position
108 and 158 of the Soluble (S-COMT) and Membranebound (MB-COMT) form of the enzyme, respectively.
Reduced COMT activity might increase the risk of breast
cancer, secondary to accumulation of CE, which causes
oxidative DNA damage. In addition, 2-CE and 4-CE may
be oxidized to CE quinones, which react with DNA to
form adduct. These adducts, especially CE-3,4-quinones
derived from 4-CE, can cause depurination leaving
apurine sites, which is the major type of genetic damage
leading to mutation and genomic deletion during
tumorigenesis (20, 21). Some findings suggest that the
allele encoding low activity COMT may be an important
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contributor to the development of breast cancer, and
also, has recently been associated with the clinical stage
and extent of metastasis of breast cancer (22).
The glutathione-dependent peroxidases (Glutathione
S-transferase) are involved in detoxification of products
of oxidative damage, by catalyzing conjugation of
glutathione with ROS. Genetic polymorphisms are known
to affect enzyme activity in GSTM1, GSTT1, GSTP1
isoenzymes. Both GSTM1 and GSTT1 enzyme activities
are absent from approximately 50% and 30% of
Caucasians, respectively, (23) and absent from 20% of
Turks for GSTT1 due to homozygous deletions of the
genes (24). An amino acid exchange at the 105 position
of GSTP1 has caused reduced activity. Because all GST
enzymes are present in human breast tissue, it is plausible
that a lack of these isozymes could increase breast cancer
risk. However, the outcomes of epidemiological studies
on GST genotypes and breast cancer have been
inconsistent (12,13, 23).
The study of the relationship among human genetic
polymorphisms, cancer susceptibility, toxicity, and
environmental exposure is a new and exciting area of
research. These person-to-person differences, which are,

in part, attributed to allelic variability or gene
polymorphisms, might define subpopulations of women
with higher lifetime exposures to hormone-dependent
growth promotion or to cellular damage from particular
estrogens and estrogen metabolites. Such variation could
explain a portion of the cancer susceptibility associated
with reproductive events and hormone exposure.
Currently, the evaluation of associations between breast
cancer risk and genetic polymorphisms in enzyme
involved in hormone metabolism may be a cost effective
manner in which to evaluate metabolic variability (5).
The studies of polymorphisms in steroid hormone
metabolizing enzymes and breast cancer risk, and those
of gene-environment interactions, have yielded conflicting
results. Therefore, there is undoubtedly a need for
elucidating the basis of breast cancer, identifying etiologic
factors and clarifying the genetic polymorphisms in
steroid hormone metabolizing genes. Molecular
epidemiological studies have increasingly important
implications for breast cancer risk assessment and the
prevention, early diagnosis and intervention of the
disease.
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